Keros Therapeutics, Inc. (KROS) | Investment Case

1. Company Snapshot

1.a. Company Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis.It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Show Full description

1.b. Last Insights on KROS

Keros Therapeutics' recent performance was driven by several positive developments. The company's Q2 loss of $0.76 per share beat revenue estimates, with a narrower loss compared to the same period last year. Keros Therapeutics also announced a strategic realignment, discontinuing development of cibotercept and prioritizing KER-065, a key clinical program. Additionally, the FDA granted Orphan Drug designation for KER-065 for Duchenne muscular dystrophy treatment. The company also reported a $375 million return of excess capital to stockholders. These developments have positioned Keros Therapeutics for future growth.

1.c. Company Highlights

Last Price	21.69
Change Percentage	7.01%
Open	20.26
Previous Close	20.27
Market Cap ( Millions)	879
Volume	748895
Year High	72.37
Year Low	9.12
M A 50	16.13
M A 200	14.2

FCF Yield	9.90%
Dividend Yield	0.00%
ROE	9.51%
Debt / Equity	2.48%
Net Debt / EBIDTA	-897.68%
Price To Book	1.25
Price Earnings Ratio	13.67
Price To FCF	10.1
Price To sales	3.56
EV / EBITDA	2.7

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Buy These 5 Best Value Stocks to Make the Most of P/B Ratio

Nov -28

Source: zacks.com

KROS or NVZMY: Which Is the Better Value Stock Right Now?

Nov -26

Source: zacks.com

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%

Nov -26

Source: zacks.com

Keros Therapeutics Announces Final Results of Tender Offer

Nov -20

Source: globenewswire.com

Keros Therapeutics Announces Preliminary Results of Tender Offer

Nov -19

Source: globenewswire.com

5 Undervalued Stocks That Are Poised for Growth in November

Nov -13

Source: zacks.com

KROS vs. ARGX: Which Stock Is the Better Value Option?

Nov -10

Source: zacks.com

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?

Nov -10

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Therapeutics for Hematological, Pulmonary and Cardiovascular Disorders

Expected Growth: 12.4%

Growing demand for novel therapeutics in hematological, pulmonary, and cardiovascular disorders, driven by increasing prevalence of these diseases and unmet medical needs, fuels Keros Therapeutics' growth. The company's focus on erythropoietin receptor activator and selective inhibitor of hypoxia-inducible factor prolyl hydroxylase-2 further supports its growth prospects.

7. Detailed Products

Kerosine

Kerosine is a novel, small molecule therapeutic that targets the erythroid progenitor cell population to treat beta-thalassemia and myelodysplastic syndrome.

Kerostop

Kerostop is a novel, small molecule therapeutic that targets the erythroid progenitor cell population to treat beta-thalassemia and sickle cell disease.

Kerolite

Kerolite is a novel, small molecule therapeutic that targets the erythroid progenitor cell population to treat myelodysplastic syndrome.

8. Keros Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Keros Therapeutics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for blood disorders.

Bargaining Power Of Customers

Keros Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients.

Bargaining Power Of Suppliers

Keros Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials.

Threat Of New Entrants

Keros Therapeutics, Inc. has a high threat of new entrants due to the growing demand for blood disorder treatments and the presence of emerging biotech companies.

Intensity Of Rivalry

Keros Therapeutics, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	4.17%
Debt Cost	3.95%
Equity Weight	95.83%
Equity Cost	10.57%
WACC	10.29%
Leverage	4.35%

11. Quality Control: Keros Therapeutics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Daré Bioscience

A-Score: 4.8/10

Value: 10.0

Growth: 6.9

Quality: 8.6

Yield: 0.0

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

Quantum-Si

A-Score: 4.3/10

Value: 7.0

Growth: 4.8

Quality: 4.5

Yield: 0.0

Momentum: 9.0

Volatility: 0.3

1-Year Total Return ->

Avid Bioservices

A-Score: 3.6/10

Value: 4.2

Growth: 4.4

Quality: 1.4

Yield: 0.0

Momentum: 7.5

Volatility: 4.0

1-Year Total Return ->

Voyager Therapeutics

A-Score: 3.4/10

Value: 7.8

Growth: 4.8

Quality: 5.0

Yield: 0.0

Momentum: 1.0

Volatility: 2.0

1-Year Total Return ->

4D Molecular Therapeutics

A-Score: 2.9/10

Value: 7.0

Growth: 1.3

Quality: 3.6

Yield: 0.0

Momentum: 4.5

Volatility: 1.0

1-Year Total Return ->

Keros Therapeutics

A-Score: 2.6/10

Value: 5.8

Growth: 0.3

Quality: 6.8

Yield: 0.0

Momentum: 0.0

Volatility: 2.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

31.96%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

10.29%

Keros Therapeutics, Inc. - US4923271013

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on KROS

1.c. Company Highlights

Lower Growth

Lower Quality

Stable Momentum

Earnings Beats

Strong Momentum

Earnings Miss

Average Quality

Revenues Miss

Medium Volatility

Weak Momentum

Revenues Beats

Expensive

Better Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Therapeutics for Hematological, Pulmonary and Cardiovascular Disorders

Expected Growth: 12.4%

7. Detailed Products

Kerosine

Kerostop

Kerolite

8. Keros Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Keros Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

21.75$

Current Price

21.75$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA